undamentalytics Newsletter

Hedge fund

Casdin Capital, LLC

13F for the quarter to June 30, 2026, filed August 14, 2026 · SEC CIK 1534261

Reported value
$2.0bn
93% in companies we cover
Positions we cover
42
Largest RVMD 24.2%
Copy, a year
+6.2%
S&P 500 +15.8%
Copy Sharpe ratio
0.29
S&P 500 0.82

How copying its 13F would have done

$10.0k$20.0k$40.0k 201620182020202220242026 $48.2k$19.1k
CopyS&P 500 $10,000 copying Casdin Capital, LLC's filed holdings in companies we cover from February 12, 2016, buying on the first trading day after each 13F was filed and holding until the next, against the S&P 500 (total return). Marked weekly, log scale. Before costs and taxes; misses trading within each quarter and anything 13F does not show (shorts, cash, bonds, non-US holdings).

Biggest drop −77.5% (S&P 500 −31.8%); beta 1.36; alpha −6.8% a year (t = −0.67); last 12 months +20.7% against +12.1%.

Reported value by quarter

Casdin Capital, LLC: 13F reported value Total value of all positions in each quarter's 13F, as filed (values before 2023 were filed in thousands of dollars and are converted).
$0 $500B $1T $1.5T Reported value, 2015-12-31: $107.4M Reported value, 2016-03-31: $84.5M Reported value, 2016-06-30: $95.7M Reported value, 2016-09-30: $123.5M Reported value, 2016-12-31: $121.1M Reported value, 2017-03-31: $169.5M Reported value, 2017-06-30: $250M Reported value, 2017-09-30: $354.2M Reported value, 2017-12-31: $409.2M Reported value, 2018-03-31: $565M Reported value, 2018-06-30: $708.7M Reported value, 2018-09-30: $814.4M Reported value, 2018-12-31: $584.5M Reported value, 2019-03-31: $910.4M Reported value, 2019-06-30: $1.1T Reported value, 2019-09-30: $966.3B Reported value, 2019-12-31: $1.1B Reported value, 2020-03-31: $942M Reported value, 2020-06-30: $1.7B Reported value, 2020-09-30: $2.2B Reported value, 2020-12-31: $3.4B Reported value, 2021-03-31: $3.4B Reported value, 2021-06-30: $3.9B Reported value, 2021-09-30: $4B Reported value, 2021-12-31: $3.5B Reported value, 2022-03-31: $2.2B Reported value, 2022-06-30: $1.2B Reported value, 2022-09-30: $1.5B Reported value, 2022-12-31: $1.3T Reported value, 2023-03-31: $1.2B Reported value, 2023-06-30: $1.1B Reported value, 2023-09-30: $896.6M Reported value, 2023-12-31: $1B Reported value, 2024-03-31: $1.3B Reported value, 2024-06-30: $1.3B Reported value, 2024-09-30: $1.5B Reported value, 2024-12-31: $1.5B Reported value, 2025-03-31: $1.2B Reported value, 2025-06-30: $1.1B Reported value, 2025-09-30: $1.2B Reported value, 2025-12-31: $1.6B Reported value, 2026-03-31: $1.3B Reported value, 2026-06-30: $2B 2015-12-31 2018-03-31 2020-06-30 2022-09-30 2026-06-30 $2B
View chart data
Period Reported value
2015-12-31 $107.4M
2016-03-31 $84.5M
2016-06-30 $95.7M
2016-09-30 $123.5M
2016-12-31 $121.1M
2017-03-31 $169.5M
2017-06-30 $250M
2017-09-30 $354.2M
2017-12-31 $409.2M
2018-03-31 $565M
2018-06-30 $708.7M
2018-09-30 $814.4M
2018-12-31 $584.5M
2019-03-31 $910.4M
2019-06-30 $1.1T
2019-09-30 $966.3B
2019-12-31 $1.1B
2020-03-31 $942M
2020-06-30 $1.7B
2020-09-30 $2.2B
2020-12-31 $3.4B
2021-03-31 $3.4B
2021-06-30 $3.9B
2021-09-30 $4B
2021-12-31 $3.5B
2022-03-31 $2.2B
2022-06-30 $1.2B
2022-09-30 $1.5B
2022-12-31 $1.3T
2023-03-31 $1.2B
2023-06-30 $1.1B
2023-09-30 $896.6M
2023-12-31 $1B
2024-03-31 $1.3B
2024-06-30 $1.3B
2024-09-30 $1.5B
2024-12-31 $1.5B
2025-03-31 $1.2B
2025-06-30 $1.1B
2025-09-30 $1.2B
2025-12-31 $1.6B
2026-03-31 $1.3B
2026-06-30 $2B

Holdings and moves

CompanyShare of portfolioValueSharesChange in shares
RVMDRevolution Medicines, Inc.24.16%$482.7m2.58M0.0%
RLAYRelay Therapeutics, Inc.15.02%$300.0m16.04M+11.2% Added
WGSGenedx Holdings Corp.12.74%$254.5m3.71M+23.3% Added
ILMNIllumina, Inc.4.67%$93.2m530.0K0.0%
LABStandard Biotools Inc.3.66%$73.0m88.78M0.0%
GPCRStructure Therapeutics Inc.3.16%$63.1m1.18M0.0%
DNLIDenali Therapeutics Inc.2.63%$52.6m2.04M+11.1% Added
NGNENeurogene Inc.2.43%$48.6m1.55M+8.8% Added
BEAMBeam Therapeutics Inc.2.32%$46.3m1.35M0.0%
TXG10x Genomics, Inc.2.02%$40.3m1.05M−53.8% Reduced
SRRKScholar Rock Holding Corp1.83%$36.6m665.0K+90.0% Added
PSNLPersonalis, Inc.1.71%$34.2m2.55M+59.4% Added
GRALGrail, Inc.1.64%$32.8m480.0K+108.7% Added
GHGuardant Health, Inc.1.39%$27.8m185.0K−41.3% Reduced
MAZEMaze Therapeutics, Inc.1.26%$25.2m843.9K+11.2% Added
HIMSHims & Hers Health, Inc.1.22%$24.3m700.0K0.0%
ALNYAlnylam Pharmaceuticals, Inc.1.13%$22.6m75.0K0.0%
TSHATaysha Gene Therapies, Inc.1.11%$22.1m3.25M0.0%
AGMBAgomab Therapeutics NV1.01%$20.1m1.55M0.0%
SEPNSepterna, Inc.0.93%$18.5m553.3K0.0%
PBLSParabilis Medicines, Inc.0.89%$17.7m645.7KNew
SIONSionna Therapeutics, Inc.0.88%$17.6m400.0KNew
VCYTVeracyte, Inc.0.81%$16.2m276.3K0.0%
ANLAdlai Nortye Group Ltd.0.72%$14.4m1.25M+132.1% Added
PRMEPrime Medicine, Inc.0.58%$11.7m3.17M0.0%
ABSIAbsci Corp0.56%$11.3m973.3K0.0%
DGXQuest Diagnostics0.53%$10.6m50.0K0.0%
SRPTSarepta Therapeutics, Inc.0.42%$8.4m470.0KNew
QUREUniqure N.V.0.35%$6.9m150.0KNew
NTLAIntellia Therapeutics, Inc.0.30%$6.0m355.0K0.0%
MRNAModerna0.26%$5.3m75.0K0.0%
IRONDisc Medicine, Inc.0.24%$4.8m65.0K0.0%
GLUEMonte Rosa Therapeutics, Inc.0.23%$4.5m186.0K0.0%
IPSCCentury Therapeutics, Inc.0.15%$3.0m1.23M0.0%
CTNMContineum Therapeutics, Inc.0.12%$2.4m148.3K0.0%
BBOTBridgebio Oncology Therapeutics, Inc.0.11%$2.2m282.3K0.0%
EDITEditas Medicine, Inc.0.07%$1.4m445.0KNew
PACBPacific Biosciences Of California, Inc.0.06%$1.2m723.8K0.0%
KARDKardigan, Inc.0.06%$1.2m50.0KNew
RXRXRecursion Pharmaceuticals, Inc.0.03%$606,735165.3K0.0%
DNAGinkgo Bioworks Holdings, Inc.0.02%$361,64636.5K0.0%
TNYATenaya Therapeutics, Inc.0.01%$267,531362.0K0.0%
CompanyBought (value)Shares
WGSGenedx Holdings Corp.$48.1m700.0K
RLAYRelay Therapeutics, Inc.$30.2m1.62M
PBLSParabilis Medicines, Inc.$17.7m645.7K
SIONSionna Therapeutics, Inc.$17.6m400.0K
SRRKScholar Rock Holding Corp$17.3m315.0K
GRALGrail, Inc.$17.1m250.0K
PSNLPersonalis, Inc.$12.7m950.0K
SRPTSarepta Therapeutics, Inc.$8.4m470.0K
ANLAdlai Nortye Group Ltd.$8.2m711.5K
QUREUniqure N.V.$6.9m150.0K
DNLIDenali Therapeutics Inc.$5.3m205.0K
NGNENeurogene Inc.$3.9m125.0K
MAZEMaze Therapeutics, Inc.$2.5m85.0K
EDITEditas Medicine, Inc.$1.4m445.0K
KARDKardigan, Inc.$1.2m50.0K

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanySold (value)Shares
TXG10x Genomics, Inc.−$47.0m−1.23M
GHGuardant Health, Inc.−$19.5m−130.0K
QGENQiagen N.V.−$14.4m−360.0K
TEMTempus AI, Inc.−$13.3m−294.1K
MLTXMoonlake Immunotherapeutics−$8.4m−450.0K

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanyValue last quarterShares
QGENQiagen N.V.$14.4m360.0K
TEMTempus AI, Inc.$13.3m294.1K
MLTXMoonlake Immunotherapeutics$8.4m450.0K
  • Health Care100.0%

Share of the value held in companies we cover, by sector.

PeriodCopy, a yearS&P 500SharpeS&P 500Biggest dropBeta
Whole backtestFebruary 12, 2016 to November 2, 2026+6.2%+15.8%0.290.82−77.5%1.36
2018 onwardsJanuary 5, 2018 to November 2, 2026+2.2%+13.9%0.190.66−77.5%1.32
Last three yearsNovember 3, 2023 to November 2, 2026+25.2%+21.8%0.651.16−43.5%1.45
Last yearNovember 7, 2025 to November 2, 2026+24.9%+14.2%0.650.84−31.6%1.52

From SEC Form 13F data sets. A 13F lists long positions in US-listed shares at the quarter's end, filed up to 45 days later; it does not show shorts, cash, bonds, non-US holdings or trades within the quarter. Positions in companies outside our coverage are not listed here. Research, not investment advice.